KU 2285

Known as: KU-2285 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1988-2005
024619882005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Sanazole (AK-2123, 3-nitrotriazole derivative, N1-(3-methoxypropyl)-2-(3-nitro-1 H-1,2,4-triazol-1-yl)acetamide) and nimorazole… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1997
1997
A fluorinated 2-nitroimidazole radiosensitizer KU-2285 was given before intraoperative radiotherapy (IORT) to 30 patients with… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1996
1996
A fluorinated 2-nitroimidazole radiosensitizer KU-2285 was given orally to 14 patients. The daily dose ranged from 0.5 to 2.0 g… (More)
Is this relevant?
1996
1996
Development of strategies to eradicate radioresistant hypoxic cells would be of great benefit for clinical radiotherapy. In the… (More)
Is this relevant?
1994
1994
PURPOSE Because reoxygenation of solid tumors after irradiation with a hypoxic cell sensitizer has never previously been… (More)
Is this relevant?
1994
1994
PURPOSE Since the radiosensitizing effect of KU-2285 at relatively low dose levels is not known, we investigated its efficacy at… (More)
Is this relevant?
1994
1994
PURPOSE The in vitro and in vivo effects of two promising hypoxic cell radiosensitizers, KIN-804 (KIN) and KU-2285 (KU), were… (More)
Is this relevant?
1993
1993
PURPOSE The in vivo radiosensitization efficacy of KU-2285 at clinically relevant low radiation doses (2-4 Gy) was compared with… (More)
Is this relevant?
1992
1992
Since the cytokinesis-block micronucleus assay is very sensitive at low radiation doses, we used it to investigate the in vitro… (More)
Is this relevant?
1991
1991
To develop new hypoxic cell radiosensitizers, we incorporated fluorine atoms into the side chain of the 2-nitroimidazole. Of the… (More)
Is this relevant?